CD274 and neoplasm: Several candidate biomarkers have been recognized, including PD-L1 expression, cancer-driven mutations, tumor-infiltrating lymphocytes (TILs) and microsatellite instability (MSI), of which PD-L1 expression is officially approved while the standardization for TILs is difficult to be established [14,15].